- Home
- ELAB
ELAB
Elevai Labs Inc.
as 01-17-2025 4:00pm EST
Stocks
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | NEWPORT BEACH |
| Market Cap: | N/A | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -61.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.74 - $218.00 | Next Earning Date: | 11-14-2024 |
| Revenue: | $2,446,161 | Revenue Growth: | 112.17% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Elevai Labs Inc. News
ELAB Breaking Stock News: Dive into ELAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture
GlobeNewswire
4 days ago
PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries
GlobeNewswire
16 days ago
PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
GlobeNewswire
17 days ago
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products
TipRanks
a month ago
Elevai Labs plans name change to PMGC Holdings, redomicile to Nevada
GlobeNewswire
a month ago
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada
GlobeNewswire
a month ago
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada
GlobeNewswire
a month ago
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
Compare ELAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELAB Elevai Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.